NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Forecast, Price & News

$0.73

0.00 (0.00%)

(As of 06/5/2023 ET)

Compare

Today's Range: $0.70
▼
$0.78
50-Day Range: $0.64
▼
$1.46
52-Week Range: $0.59
▼
$2.80

Volume: 185,297 shs
Average Volume: 185,051 shs
Market Capitalization: $23.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Better Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 858.9% Upside
$7.00 Price Target
Short Interest: Healthy
4.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$447,794 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.33) to ($0.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

572nd out of 985 stocks

Health Services Industry

8th out of 13 stocks

3.3

Analyst's Opinion

Consensus Rating
Better Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Better Therapeutics has a forecasted upside of 858.9% from its current price of $0.73.
Amount of Analyst Coverage
Better Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.79% of the float of Better Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Better Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Better Therapeutics has recently increased by 19.11%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Better Therapeutics does not currently pay a dividend.
Dividend Growth
Better Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BTTX.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for BTTX on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Better Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Better Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $447,794.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
59.40% of the stock of Better Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.46% of the stock of Better Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Better Therapeutics are expected to grow in the coming year, from ($1.33) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Better Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Better Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Better Therapeutics (NASDAQ:BTTX) Stock

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTTX Stock News Headlines

May 17, 2023 | insidermonkey.com

Better Therapeutics, Inc. (NASDAQ:BTTX) Q1 2023 Earnings Call Transcript

May 16, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Hold Rating on Better Therapeutics, Inc. (BTTX)

June 6, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 11, 2023 | msn.com

Better Therapeutics: Q1 Earnings Insights

May 11, 2023 | markets.businessinsider.com

Chardan Capital Remains a Buy on Better Therapeutics, Inc. (BTTX)

May 11, 2023 | msn.com

Better Therapeutics GAAP EPS of -$0.39

May 11, 2023 | finance.yahoo.com

Better Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 10, 2023 | msn.com

Better Therapeutics's Earnings: A Preview

June 6, 2023 | Vector Vest (Ad)

Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 4, 2023 | finance.yahoo.com

Better Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

April 15, 2023 | americanbankingnews.com

Lake Street Capital Lowers Better Therapeutics (NASDAQ:BTTX) Price Target to $5.00

April 13, 2023 | americanbankingnews.com

Geoffrey M. Parker Buys 303,030 Shares of Better Therapeutics, Inc. (NASDAQ:BTTX) Stock

April 13, 2023 | americanbankingnews.com

Better Therapeutics, Inc. (NASDAQ:BTTX) Insider Frank Karbe Buys 242,424 Shares of Stock

April 13, 2023 | msn.com

Better Therapeutics up 8% on raising ~$6.5M

April 8, 2023 | seekingalpha.com

Better Therapeutics announces equity offering to raise $6.5M

April 8, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Better Therapeutics, Inc. (NASDAQ:BTTX) Increased by Analyst

April 6, 2023 | finance.yahoo.com

Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade

April 6, 2023 | msn.com

Better Therapeutics launches private placement to raise $6.5M

April 6, 2023 | finance.yahoo.com

Better Therapeutics Announces $6.5MM Private Placement

April 4, 2023 | americanbankingnews.com

Better Therapeutics (NASDAQ:BTTX) Downgraded by Lifesci Capital

April 3, 2023 | americanbankingnews.com

Better Therapeutics (NASDAQ:BTTX) PT Lowered to $9.00 at Chardan Capital

April 1, 2023 | seekingalpha.com

Better Therapeutics, Inc. (BTTX) Q4 2022 Financial Results Conference Call Transcript

April 1, 2023 | marketwatch.com

Y-mAbs Therapeutics Shares Soar 70% After Surprise 4Q Profit

March 30, 2023 | msn.com

Better Therapeutics GAAP EPS of -$0.37 beats by $0.13

March 30, 2023 | marketwatch.com

Natural Killer Cells Therapeutics Market Top Players by 2031

March 30, 2023 | finance.yahoo.com

Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 29, 2023 | benzinga.com

A Preview Of Better Therapeutics's Earnings

See More Headlines

BTTX Price History

30 days | 90 days | 365 days | Advanced Chart

BTTX Company Calendar

Today: 6/06/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health services
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BTTX
CUSIP: N/A
CIK: 1832415
Web: mcacquisition.com
Phone: 415-887-2311
Fax: N/A
Employees: 44
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.00
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +858.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,082.89%
Return on Assets: -156.14%

Debt

Debt-to-Equity Ratio: 1.61
Current Ratio: 0.62
Quick Ratio: 0.62

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 2,316.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.04) per share
Price / Book: -18.25

Miscellaneous

Outstanding Shares: 31,731,000
Free Float: 12,883,000
Market Cap: $23.16 million
Optionable: Not Optionable
Beta: 1.57

Key Executives

Mr. David P. Perry M.B.A. (Age 55)
Co-Founder & Exec. Chairman
Comp: $194.71k

Dr. Mark A. Berman M.D. (Age 48)
Chief Medical Officer
Comp: $576.38k

Ms. Kristin Wynholds (Age 51)
Chief Product Officer
Comp: $586.5k

Mr. Frank L. Karbe (Age 55)
CEO, Pres & Director

Mr. Mark Heinen (Age 54)
Head of Fin. & Interim CFO

Mr. Andres Camacho
Sr. VP of Technology & Head of Engineering

Mr. Thiago Licias De Oliveira
Chief People Officer

Ms. Diane Gomez-Thinnes
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTTX Stock - Frequently Asked Questions

Should I buy or sell Better Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTTX shares.
View BTTX analyst ratings or view top-rated stocks.
What is Better Therapeutics' stock price forecast for 2023?: 3 equities research analysts have issued 1-year price objectives for Better Therapeutics' stock. Their BTTX share price forecasts range from $5.00 to $9.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 858.9% from the stock's current price.
View analysts price targets for BTTX or view top-rated stocks among Wall Street analysts.
How have BTTX shares performed in 2023?: Better Therapeutics' stock was trading at $1.1050 on January 1st, 2023. Since then, BTTX shares have decreased by 33.9% and is now trading at $0.73.
View the best growth stocks for 2023 here.
Are investors shorting Better Therapeutics?: Better Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 154,600 shares, an increase of 19.1% from the April 30th total of 129,800 shares. Based on an average daily volume of 128,100 shares, the short-interest ratio is presently 1.2 days. Approximately 4.8% of the company's shares are sold short.
View Better Therapeutics' Short Interest.
When is Better Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BTTX earnings forecast.

What is Better Therapeutics' stock symbol?: Better Therapeutics trades on the NASDAQ under the ticker symbol "BTTX."
Who are Better Therapeutics' major shareholders?: Better Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (2.93%). Insiders that own company stock include Andrew J Armanino, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark Heinen and Risa J Lavizzo-Mourey.
View institutional ownership trends.
How do I buy shares of Better Therapeutics?: Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Better Therapeutics' stock price today?: One share of BTTX stock can currently be purchased for approximately $0.73.
How much money does Better Therapeutics make?: Better Therapeutics (NASDAQ:BTTX) has a market capitalization of $23.16 million and generates $10,000.00 in revenue each year. The company earns $-39,760,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.
How can I contact Better Therapeutics?: Better Therapeutics' mailing address is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. The official website for the company is mcacquisition.com. The company can be reached via phone at 415-887-2311 or via email at mcac@icrinc.com.

This page (NASDAQ:BTTX) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial